Antisense Oligonucleotides for Kennedy's Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and cures are lacking for Kennedy's Disease, a neuromuscular degenerative disorder caused by expansion of a CAG trinucleotide repeat in the Androgen Receptor gene, leading to motor neuron degeneration and muscle wasting, with no effective methods to prevent or treat the disease.
Innovation Solution
Administration of antisense compounds targeted to the Androgen Receptor (AR) to ameliorate, treat, or prevent Kennedy's Disease by inhibiting muscle denervation, improving muscle atrophy, and increasing muscle strength in subjects with AR gene mutations, using modified oligonucleotides with specific nucleobase sequences and internucleoside linkages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is administered, then the disease progresses with muscle wasting and motor neuron degeneration, but there are no effective treatments available to counteract this progression
Solution Approach 1:
Antisense oligonucleotides serve as intermediary molecules that bind to specific RNA sequences to modulate gene expression. The compounds act as mediators between the harmful mutant androgen receptor protein and the desired therapeutic outcome by selectively depleting toxic AR isoforms while preserving full-length AR function, thereby treating Kennedy's disease without completely eliminating androgen receptor activity
Solution Approach 2:
The invention changes the parameter of androgen receptor protein isoform distribution by using antisense oligonucleotides to selectively reduce toxic truncated AR isoforms (ΔF-AR, ΔG-AR, etc.) while maintaining full-length AR expression. This selective parameter change in protein isoform levels achieves therapeutic effect without complete receptor blockade
2Object-generated harmful factors
If antisense compounds are administered to inhibit AR expression, then muscle strength loss and atrophy are prevented, but complete AR inhibition may cause adverse effects
Solution Approach 1:
The antisense oligonucleotides exhibit local quality by selectively targeting specific RNA sequences that give rise to toxic AR isoforms. Different compounds are designed to bind to specific exon regions (exon 1, 2, 3, or 4) to selectively deplete particular truncated AR isoforms (ΔF-AR, ΔG-AR, ΔH-AR, etc.) while leaving full-length AR expression intact, achieving localized molecular intervention
Solution Approach 2:
The invention applies partial action by selectively inhibiting only the toxic truncated AR isoforms rather than completely blocking all androgen receptor activity. The antisense oligonucleotides are designed to reduce specific harmful isoform levels by approximately 50% or more while preserving sufficient full-length AR function to maintain normal physiological androgen signaling and avoid adverse effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense compounds effectively inhibit AR expression, preventing muscle strength loss, atrophy, and denervation, thereby treating or preventing Kennedy's Disease in subjects with AR gene mutations associated with the CAG trinucleotide repeat expansion.
Implementation Method 1
administering an antisense compound targeted to AR
Implementation Method 2
antisense compounds targeted to the Androgen Receptor (AR)
Implementation Method 3
inhibiting AR expression
Data Source
AI summary
Certain embodiments are directed to methods of ameliorating, treating, or preventing Kennedy's Disease in a subject carrying a mutation in the Androgen Receptor (AR) gene, such as expansion of a CAG trinucleotide repeat, which is associated with Kennedy's Disease, by administering an antisense compound targeted to AR.